Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria
Medicinal Research Reviews · 2026
DOI: 10.1002/med.70055 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2026. Verfasst von Wisam A Dawood und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biomedicine and Glycomics, Griffith University, Southport, Queensland, Australia. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Hydroxamic Acids, Antimalarials, Malaria. Die Arbeit nennt 226 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australian Government Research Training Program, National Health and Medical Council of Australia, Australian Research Council.
Abstract (Originalsprache)
Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa. Malaria eradication is a global priority; however, progress has been hampered by the lack of broadly applicable and highly effective vaccines and by parasite drug resistance. To address drug resistance, the discovery of drugs with novel modes of action is crucial. Histone/lysine deacetylases (HDACs) are enzymes that control the posttranslational modification of lysine acetylation on histone and non‐histone proteins. Due to their essential roles in regulating key processes in Plasmodium parasites, including transcriptional and developmental control, HDACs are prospective drug targets for malaria. Here, the potential of HDAC inhibitors as antimalarial drug leads is reviewed, including an assessment of antiplasmodial structure‐activity relationships for more than 750 hydroxamic acids with published in vitro activity against P. falciparum . These comparative data provide unprecedented insights into potency, selectivity and physicochemical properties that can help to guide investigations of this chemotype as drug leads for malaria and other parasitic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Biomedicine and Glycomics, Griffith University, Southport, Queensland, Australia.
- School of Environment and Sciences, Griffith University, Nathan, Queensland, Australia.
- Institut für pharmazeutische und medizinische Chemie, Heinrich-Heine Universität, Germany.
- Centre for Chemistry and Drug Discovery, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
- Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
ORCID-Profile: Wisam A Dawood, Jacinta R Macdonald, Tina S Skinner-Adams, Thomas Kurz, Katherine T Andrews
Förderung
- Australian Government Research Training Program
- National Health and Medical Council of Australia
- Australian Research Council
Zitieren
APA
Dawood, W. A., Macdonald, J. R., Anzenhofer, C., Skinner-Adams, T. S., Reid, R. C., Kurz, T., Fairlie, D. P., & Andrews, K. T. (2026). Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria. Medicinal Research Reviews. https://doi.org/10.1002/med.70055
Vancouver
Dawood WA, Macdonald JR, Anzenhofer C, Skinner-Adams TS, Reid RC, Kurz T, et al. Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria. Medicinal Research Reviews. 2026. doi:10.1002/med.70055
BibTeX
@article{Dawood2026,
author = {Dawood, Wisam A and Macdonald, Jacinta R and Anzenhofer, Christian and Skinner-Adams, Tina S and Reid, Robert C and Kurz, Thomas and Fairlie, David P and Andrews, Katherine T},
title = {Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70055}
}
EUVIMED